CY1122826T1 - Προ-συντηξης rsv f αντιγονα - Google Patents

Προ-συντηξης rsv f αντιγονα

Info

Publication number
CY1122826T1
CY1122826T1 CY20201100283T CY201100283T CY1122826T1 CY 1122826 T1 CY1122826 T1 CY 1122826T1 CY 20201100283 T CY20201100283 T CY 20201100283T CY 201100283 T CY201100283 T CY 201100283T CY 1122826 T1 CY1122826 T1 CY 1122826T1
Authority
CY
Cyprus
Prior art keywords
fusion
antigons
rsv
fusion rsv
relates
Prior art date
Application number
CY20201100283T
Other languages
English (en)
Inventor
Kurt Swanson
Andrea Carfi
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1122826T1 publication Critical patent/CY1122826T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η εφεύρεση αφορά σε προ-σύντηξης RSV F πρωτεΐνη και πολυπεπτίδια που περιέχουν μία ή περισσότερες μεταλλάξεις αμινοξέος που σταθεροποιούν τη προ-σύντηξης διαμόρφωση ή αποσταθεροποιούν τη μετά τη σύντηξη διαμόρφωση. Η εφεύρεση επίσης αφορά σε μεθόδους για διέγερση ανοσοαπόκρισης προς προ-σύντηξης RSV F.
CY20201100283T 2011-05-13 2020-03-26 Προ-συντηξης rsv f αντιγονα CY1122826T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486005P 2011-05-13 2011-05-13
PCT/US2012/037773 WO2012158613A1 (en) 2011-05-13 2012-05-14 Pre-fusion rsv f antigens
EP12722057.2A EP2707385B1 (en) 2011-05-13 2012-05-14 Pre-fusion rsv f antigens

Publications (1)

Publication Number Publication Date
CY1122826T1 true CY1122826T1 (el) 2021-05-05

Family

ID=46124783

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171101209T CY1119849T1 (el) 2011-05-13 2017-11-17 Προ-συντηξης rsv f αντιγονα
CY20201100283T CY1122826T1 (el) 2011-05-13 2020-03-26 Προ-συντηξης rsv f αντιγονα

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171101209T CY1119849T1 (el) 2011-05-13 2017-11-17 Προ-συντηξης rsv f αντιγονα

Country Status (23)

Country Link
US (7) US20140248314A1 (el)
EP (2) EP3275892B1 (el)
JP (1) JP2014519819A (el)
CN (1) CN103842374A (el)
AU (1) AU2012255971A1 (el)
BR (1) BR112013029169B1 (el)
CA (1) CA2835644C (el)
CY (2) CY1119849T1 (el)
DK (2) DK3275892T3 (el)
ES (2) ES2782119T3 (el)
FR (1) FR23C1046I1 (el)
HR (2) HRP20171703T1 (el)
HU (2) HUE034673T2 (el)
LT (2) LT2707385T (el)
MX (1) MX351011B (el)
NO (1) NO2707385T3 (el)
PL (2) PL2707385T3 (el)
PT (2) PT2707385T (el)
RS (1) RS56748B1 (el)
RU (1) RU2013155485A (el)
SG (1) SG194755A1 (el)
SI (2) SI3275892T1 (el)
WO (1) WO2012158613A1 (el)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
DK2591114T3 (en) 2010-07-06 2016-08-29 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
WO2012006378A1 (en) 2010-07-06 2012-01-12 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK2611461T3 (da) 2010-08-31 2022-05-16 Glaxosmithkline Biologicals Sa Pegylerede liposomer til afgivelse af RNA, der koder immunogen
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
ES2656050T3 (es) * 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
JP2016506416A (ja) * 2013-01-10 2016-03-03 ノバルティス アーゲー インフルエンザウイルス免疫原性組成物およびその使用
US10017543B2 (en) * 2013-03-13 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US10232032B2 (en) 2013-03-14 2019-03-19 Emory University Recombinant RSV with silent mutations, vaccines, and methods related thereto
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EA035522B1 (ru) * 2013-04-25 2020-06-29 Янссен Вэксинс Энд Превеншн Б.В. Стабильные растворимые f-полипептиды rsv в конформации "до слияния"
CN105408348B (zh) * 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
US10125172B2 (en) 2013-07-25 2018-11-13 Calder Biosciences Inc. Conformationally stabilized RSV pre-fusion F proteins
US20150110825A1 (en) * 2013-09-24 2015-04-23 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
CN107073100B (zh) * 2014-09-23 2021-02-26 勃林格殷格翰动物保健美国公司 Fmdv重组疫苗及其用途
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EP3236998A1 (en) 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant metapneumovirus f proteins and their use
CN107406835A (zh) 2015-01-20 2017-11-28 美利坚合众国,由健康及人类服务部部长代表 表达嵌合rsv/bpiv3f蛋白的重组人/牛副流感病毒3(b/hpiv3)及其用途
EP3821906A1 (en) 2015-07-07 2021-05-19 Janssen Vaccines & Prevention B.V. Vaccine against rsv comprising modified f polypeptide
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
CN108348593B (zh) * 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
EP3344288A1 (en) * 2015-09-02 2018-07-11 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
BR112018008708A2 (pt) * 2015-10-29 2018-11-06 Univ Emory rsv quimérico, composições imunogênicas e métodos de uso
AU2016379097C1 (en) * 2015-12-23 2021-04-08 Pfizer Inc. RSV F protein mutants
EP3436064A1 (en) * 2016-03-29 2019-02-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion rsv f proteins and their use
PE20190420A1 (es) 2016-04-05 2019-03-19 Janssen Vaccines And Prevention B V Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
IL262109B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V vaccine against rsv
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
MY194419A (en) 2016-05-30 2022-11-30 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
CN110352072A (zh) * 2016-10-03 2019-10-18 马萨诸塞大学 用于免疫免疫前受试者以抵抗呼吸道合胞病毒(rsv)的方法
CN106432438A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432437A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106749556A (zh) * 2016-11-28 2017-05-31 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432436A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106749555A (zh) * 2016-11-28 2017-05-31 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106518988A (zh) * 2016-11-28 2017-03-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106397547A (zh) * 2016-11-28 2017-02-15 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432439A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432435A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS VACCINE
WO2018170347A1 (en) * 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
MX2019011599A (es) * 2017-03-30 2019-12-19 Univ Queensland Moleculas quimericas y usos de las mismas.
CA3058794A1 (en) 2017-04-04 2018-10-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
BR112019023477A2 (pt) 2017-05-08 2020-06-30 Gritstone Oncology, Inc. vetores de neoantígeno de alfavírus
KR102658198B1 (ko) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
CN110603058A (zh) 2017-05-15 2019-12-20 扬森疫苗与预防公司 含有病毒的稳定组合物
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
US12016919B2 (en) 2017-05-30 2024-06-25 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
AU2018285412B2 (en) * 2017-06-14 2022-06-23 Universität Zürich Cyclic peptides for protection against respiratory syncytial virus
JP7566315B2 (ja) 2017-08-07 2024-10-15 カルダー・バイオサイエンシズ・インコーポレイテッド コンフォメーションが安定化されたｒｓｖ融合前ｆタンパク質
MX2020002876A (es) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention Bv Metodo para la induccion segura de inmunidad contra el vsr.
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
EP3758747A1 (en) 2018-02-28 2021-01-06 University of Washington Self-asssembling nanostructure vaccines
US11623004B2 (en) * 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
WO2019202035A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
KR20210091749A (ko) 2018-11-13 2021-07-22 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합전 rsv f 단백질
WO2020124846A1 (zh) * 2018-12-18 2020-06-25 珠海泰诺麦博生物技术有限公司 抗呼吸道合胞病毒的中和抗体及其应用
CN109851678A (zh) * 2019-03-07 2019-06-07 苏州宇之波生物科技有限公司 一种改良的亚稳定态牛呼吸道合胞病毒融合前体f蛋白质及编码的dna分子和其应用
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
JP2022535091A (ja) 2019-06-05 2022-08-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
EP4025587A1 (en) 2019-09-04 2022-07-13 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
EP4142785A2 (en) * 2020-04-29 2023-03-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant human metapneumovirus f proteins and their use
CN113801206B (zh) * 2020-06-15 2024-07-02 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
WO2021253172A1 (zh) * 2020-06-15 2021-12-23 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023069887A1 (en) * 2021-10-18 2023-04-27 Yang, Kejian Mucosal vaccine, methods of use and administration thereof
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2024100583A1 (en) * 2022-11-09 2024-05-16 Seqirus Inc. Stabilized vaccines
WO2024151586A2 (en) * 2023-01-09 2024-07-18 Board Of Regents, The University Of Texas System Prefusion-stabilized human parainfluenza virus 3 f proteins
WO2024175040A1 (en) * 2023-02-22 2024-08-29 Everest Medicines (China) Co., Ltd. RSV mRNA VACCINES
CN118108812A (zh) * 2023-05-04 2024-05-31 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
CN117736278A (zh) * 2023-12-25 2024-03-22 英诺特（唐山）生物技术有限公司 一种用于检测呼吸道合胞病毒感染的试剂盒及检测方法
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US120A (en) 1837-02-10 Mode of constructing steelyard-balances
US4186745A (en) 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3485094D1 (de) 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JPH0731857B2 (ja) 1988-02-19 1995-04-10 三洋電機株式会社 磁気記録再生装置におけるリール台駆動装置
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
DE69031305T2 (de) 1989-11-03 1998-03-26 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DK0582581T3 (da) 1991-03-01 1999-11-08 Minnesota Mining & Mfg 1,2-substituerede 1H-imidazo[4,5-c]quinolin-4-aminer
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
PL178578B1 (pl) 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
EP0708772B1 (en) 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5397307A (en) 1993-12-07 1995-03-14 Schneider (Usa) Inc. Drug delivery PTCA catheter and method for drug delivery
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3403233B2 (ja) 1994-01-20 2003-05-06 テルモ株式会社 バルーンカテーテル
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
DE69536153D1 (de) 1994-11-17 2011-05-05 Ich Productions Ltd Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
US6090619A (en) 1997-09-08 2000-07-18 University Of Florida Materials and methods for intracellular delivery of biologically active molecules
EP0980280B1 (en) 1997-10-01 2005-02-09 Medtronic Ave, Inc. Drug delivery and gene therapy delivery system
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP2002511423A (ja) 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
ATE276199T1 (de) 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
ATE272410T1 (de) 1999-03-26 2004-08-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
OA12028A (en) 1999-09-25 2006-04-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
JP4341949B2 (ja) 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
EP1317442B1 (en) 2000-09-11 2005-11-16 Chiron Corporation Quinolinone derivatives as tyrosine kinase inhibitors
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
AP2004003069A0 (en) 2001-11-27 2004-06-30 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
CA2480638C (en) 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US6743920B2 (en) 2002-05-29 2004-06-01 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
EP1551228B1 (en) 2002-06-13 2012-10-03 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
US7250443B2 (en) 2002-08-23 2007-07-31 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
CA2756797C (en) 2002-12-23 2015-05-05 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
CN1964626A (zh) 2004-03-31 2007-05-16 纽约大学 新型合成c－糖脂、其合成及其治疗传染病、癌症和自身免疫性疾病的用途
ES2409782T3 (es) 2004-04-05 2013-06-27 Zoetis P Llc Emulsiones de aceite en agua microfluidificadas y composiciones de vacuna
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
WO2006011060A2 (en) 2004-07-23 2006-02-02 Chiron Srl Polypeptides for oligomeric assembly of antigens
ES2597439T3 (es) * 2007-12-24 2017-01-18 Id Biomedical Corporation Of Quebec Antígenos recombinantes del VSR
US8466167B2 (en) 2008-03-03 2013-06-18 Irm Llc Compounds and compositions as TLR activity modulators
WO2009132206A1 (en) 2008-04-25 2009-10-29 Liquidia Technologies, Inc. Compositions and methods for intracellular delivery and release of cargo
MA33449B1 (fr) 2009-06-24 2012-07-03 Glaxosmithkline Biolog Sa Antigènes recombinants du vrs
CA2766205A1 (en) * 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine comprising at least two paramyxovirus f protein antigens
ES2918381T3 (es) * 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use

Also Published As

Publication number Publication date
HUE048777T2 (hu) 2020-08-28
EP2707385A1 (en) 2014-03-19
PL3275892T3 (pl) 2020-09-07
LT2707385T (lt) 2017-12-11
FR23C1046I1 (fr) 2024-01-12
DK3275892T3 (da) 2020-04-06
SG194755A1 (en) 2013-12-30
HRP20171703T1 (hr) 2017-12-15
PT3275892T (pt) 2020-04-08
HUE034673T2 (en) 2018-02-28
EP2707385B1 (en) 2017-09-20
AU2012255971A1 (en) 2013-05-02
US20140248314A1 (en) 2014-09-04
LT3275892T (lt) 2020-04-10
US20220332767A1 (en) 2022-10-20
CA2835644A1 (en) 2012-11-22
CA2835644C (en) 2021-06-15
US20180237476A1 (en) 2018-08-23
US20240239845A1 (en) 2024-07-18
US20210269489A1 (en) 2021-09-02
US20220332766A1 (en) 2022-10-20
ES2651143T3 (es) 2018-01-24
EP3275892B1 (en) 2020-01-08
HRP20200451T1 (hr) 2020-06-26
BR112013029169A2 (pt) 2017-09-19
MX2013013133A (es) 2014-02-20
PL2707385T3 (pl) 2018-03-30
ES2782119T3 (es) 2020-09-10
WO2012158613A1 (en) 2012-11-22
EP3275892A3 (en) 2018-03-14
EP3275892A2 (en) 2018-01-31
US20230287056A1 (en) 2023-09-14
BR112013029169B1 (pt) 2021-09-28
PT2707385T (pt) 2017-12-19
RS56748B1 (sr) 2018-03-30
CY1119849T1 (el) 2018-06-27
RU2013155485A (ru) 2015-06-20
CN103842374A (zh) 2014-06-04
SI2707385T1 (en) 2018-01-31
JP2014519819A (ja) 2014-08-21
MX351011B (es) 2017-09-28
DK2707385T3 (da) 2017-11-20
SI3275892T1 (sl) 2020-06-30
NO2707385T3 (el) 2018-02-17

Similar Documents

Publication Publication Date Title
CY1122826T1 (el) Προ-συντηξης rsv f αντιγονα
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1124096T1 (el) Αντισωματα τα οποια στοχευουν αντιγονο ωριμανσης β-κυτταρων και μεθοδοι χρησης
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CY1118869T1 (el) Παραγωγα αμιδο σπειροκυκλικου αμιδιου και σουλφοναμιδιου
CY1124867T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1125436T1 (el) Αναστολεις dna-pk
CY1121691T1 (el) Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου
CY1123407T1 (el) Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης
CY1123259T1 (el) Αντισωματα anti-pvrig και μεθοδοι χρησης
CY1123563T1 (el) Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1120517T1 (el) Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια
CY1119489T1 (el) Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
UY34254A (es) Proteínas y péptidos modificados.
CY1120132T1 (el) Χρηση ρ3 πρωτεϊνων συντηξης βακτηριοφαγου ως παραγοντων δεσμευσης αμυλοειδους
UY35716A (es) Proteínas de unión al antígeno gitr
UY34885A (es) Proteínas de unión anti-mesotelina